HK1256793A1 - 用於治療或者預防血液癌症的化合物和方法 - Google Patents

用於治療或者預防血液癌症的化合物和方法

Info

Publication number
HK1256793A1
HK1256793A1 HK18115876.7A HK18115876A HK1256793A1 HK 1256793 A1 HK1256793 A1 HK 1256793A1 HK 18115876 A HK18115876 A HK 18115876A HK 1256793 A1 HK1256793 A1 HK 1256793A1
Authority
HK
Hong Kong
Prior art keywords
treating
compounds
methods useful
hematological cancers
preventing hematological
Prior art date
Application number
HK18115876.7A
Other languages
English (en)
Inventor
David B Sykes
David Scadden
Timothy A Lewis
Andreas Janzer
Hanna Meyer
Detlef Stöckigt
Original Assignee
布羅德研究所股份有限公司
通用醫療公司
拜耳醫藥股份公司
哈佛大學的校長及成員們
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 布羅德研究所股份有限公司, 通用醫療公司, 拜耳醫藥股份公司, 哈佛大學的校長及成員們 filed Critical 布羅德研究所股份有限公司
Publication of HK1256793A1 publication Critical patent/HK1256793A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18115876.7A 2015-09-01 2018-12-11 用於治療或者預防血液癌症的化合物和方法 HK1256793A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562212992P 2015-09-01 2015-09-01
US201662329796P 2016-04-29 2016-04-29
PCT/EP2016/070320 WO2017037022A1 (en) 2015-09-01 2016-08-29 Compounds and methods useful for treating or preventing hematological cancers

Publications (1)

Publication Number Publication Date
HK1256793A1 true HK1256793A1 (zh) 2019-10-04

Family

ID=56889049

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18115876.7A HK1256793A1 (zh) 2015-09-01 2018-12-11 用於治療或者預防血液癌症的化合物和方法

Country Status (7)

Country Link
US (2) US11096934B2 (zh)
EP (1) EP3344243B1 (zh)
JP (1) JP6917375B2 (zh)
CN (2) CN108472280A (zh)
CA (1) CA2996632C (zh)
HK (1) HK1256793A1 (zh)
WO (1) WO2017037022A1 (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699023A (zh) * 2015-12-30 2018-10-23 安吉奥斯医药品有限公司 掺入突变型异柠檬酸脱氢酶的肿瘤的治疗
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN108721280A (zh) * 2017-04-20 2018-11-02 华东理工大学 来氟米特和特立氟胺在白血病治疗中的应用
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
MX2020008678A (es) 2018-02-20 2020-09-25 Servier Lab Metodos de uso para derivados de benzotriazol trisustituidos.
JP2021519334A (ja) * 2018-03-26 2021-08-10 クリア クリーク バイオ， インコーポレイテッド ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法
WO2019191030A1 (en) * 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Methods of determining dosing of a therapeutic agent based on measured levels of a metabolite
EP3858361A4 (en) * 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
JP7409670B2 (ja) * 2018-12-21 2024-01-09 国立大学法人北海道大学 多能性幹細胞を除去するための組成物、及び多能性幹細胞の除去方法
WO2020242773A1 (en) * 2019-05-31 2020-12-03 Clear Creek Bio, Inc. Methods of promoting differentiation of myeloid-derived suppressor cells using inhibitors of dihydroorotate dehydrogenase
EP4003351A4 (en) * 2019-07-23 2023-08-23 City of Hope METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2021061874A2 (en) * 2019-09-23 2021-04-01 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
CA3165475A1 (en) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase in combination with an anti-cd38 therapeutic agent
CA3175964A1 (en) * 2020-03-20 2021-09-23 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
US20210315880A1 (en) * 2020-03-20 2021-10-14 Clear Creek Bio, Inc. Methods of treating viral infections using inhibitors of nucleotide synthesis pathways
EP3960170A1 (en) 2020-08-25 2022-03-02 Bayer AG Dosing schedule for a method of treatment with dhodh inhibitors
WO2022167402A1 (en) * 2021-02-02 2022-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683902A (en) * 1970-06-24 1972-08-15 Anatoly Ivanovich Artemenko Medical splint apparatus
DE19539638A1 (de) * 1995-10-25 1997-04-30 Hoechst Ag Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen
WO1998013047A1 (en) * 1996-09-26 1998-04-02 Williams, James, W. Improved therapeutic uses of 4-quinoline-carboxylic acid derivatives
CN104739821B (zh) 2009-09-18 2018-04-06 赛诺菲 稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
JP6162709B2 (ja) * 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法

Also Published As

Publication number Publication date
EP3344243B1 (en) 2020-12-09
CA2996632A1 (en) 2017-03-09
CA2996632C (en) 2023-10-17
WO2017037022A1 (en) 2017-03-09
US11096934B2 (en) 2021-08-24
CN108472280A (zh) 2018-08-31
US20180263970A1 (en) 2018-09-20
CN114288294A (zh) 2022-04-08
US20220016106A1 (en) 2022-01-20
JP2018529761A (ja) 2018-10-11
EP3344243A1 (en) 2018-07-11
JP6917375B2 (ja) 2021-08-11

Similar Documents

Publication Publication Date Title
HK1256793A1 (zh) 用於治療或者預防血液癌症的化合物和方法
IL267247B (en) Compositions and methods for treating cancer
HK1251407A1 (zh) 治療癌症的方法
IL263224A (en) Methods and preparations for the treatment of cancer
IL304820A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
PT3377516T (pt) Composição para o tratamento do cancro
HK1255815A1 (zh) 治療腹膜癌的組合物和方法
HK1244217A1 (zh) 用於治療蛋白質病的方法
LT3200815T (lt) Būdai ir kompozicijos, skirti vėžio gydymui
IL256523A (en) Compositions and methods for treating cancer
HK1250944A1 (zh) 用於治療癌症的方法
ZA201804142B (en) Compositions and methods for detecting and treating esophageal cancer
HK1250942A1 (zh) 用於治療癌症的方法
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
ZA201900939B (en) Combination treatment for hematological cancers
HK1250943A1 (zh) 用於治療癌症的方法
IL255638A (en) Compositions and methods for treating cancer
PL3397964T3 (pl) Kompozycje i sposoby do wykrywania i leczenia raka jajnika
EP3303289A4 (en) Compounds and methods for treating cancer
ZA201802268B (en) Methods and compositions for preventing or treating cancer
HK1250958A1 (zh) 用於治療癌症的組合物和方法
GB201609402D0 (en) Materials and methods for treating cancer